Minimal change disease in a patient receiving IFN-alpha therapy for chronic hepatitis C virus infection

Area of Science:

• Nephrology
• Hepatology
• Immunology

Background:

• Chronic hepatitis C virus (HCV) infection is linked to various extrahepatic manifestations, including renal disorders.
• Membranoproliferative glomerulonephritis (MPGN), both cryoglobulinemic and non-cryoglobulinemic, represents a principal renal complication.
• Interferon-alpha (IFN-alpha) therapy, commonly used for HCV, has been implicated in precipitating or exacerbating MPGN.

Observation:

• A 32-year-old male with chronic HCV infection received IFN-alpha treatment for chronic active hepatitis.
• Following prolonged IFN-alpha therapy, the patient developed significant edema, proteinuria, and hypoalbuminemia.
• Laboratory findings included elevated cholesterol, positive cryoglobulin, and substantial daily protein excretion in urine.

Findings:

• Despite initial suspicion of cryoglobulinemic MPGN, a kidney biopsy revealed minimal change disease (MCD).
• This case highlights a potential, albeit unusual, progression from HCV infection and IFN-alpha treatment to MCD.
• The interplay between HCV, cryoglobulinemia, IFN-alpha, and the development of specific glomerular pathologies warrants further investigation.

Implications:

• This case underscores the importance of vigilant renal monitoring in patients with chronic HCV undergoing IFN-alpha therapy.
• It suggests that IFN-alpha might trigger or unmask glomerular diseases beyond the typical MPGN associated with HCV.
• Further research is needed to elucidate the mechanisms by which HCV and its treatment can influence diverse renal pathologies like MCD.